177 results about "Minoxidil" patented technology

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The invention discloses a product capable of treating androgenetic alopecia and / or promoting hair growth and application of exosomes, the product comprises the product capable of treating androgenetic alopecia and / or promoting hair growth, and is characterized by comprising the exosomes obtained by stimulating mesenchymal stem cells through CHIR99021 and minoxidil combined with the exosomes. The disclosure verifies that the exosome obtained by stimulating mesenchymal stem cells through CHIR99021 can promote hair growth and treat androgenetic alopecia, and particularly, the hair growth effect is better when the exosome is combined with minoxidil, so that a product comprising the exosome and minoxidil can treat androgenetic alopecia and promote hair growth is provided.

The invention relates to the technical field of pharmaceutical preparations, and provides a minoxidil film coating agent as well as a preparation method and application thereof. The minoxidil film coating agent provided by the invention comprises 40-60% of propylene glycol, 3-7% of polyvinyl alcohol, 20-30% of ethanol, 1-7% of minoxidil and the balance of water. According to the invention, propylene glycol is taken as a solvent, a plasticizer and a transdermal absorption enhancer, polyvinyl alcohol is taken as a film-forming material, and ethanol is taken as a volatile agent, after administration, ethanol is volatilized to promote film formation of polyvinyl alcohol, and propylene glycol enhances the plasticity of the formed film, so that the effect of reducing liquid medicine loss is achieved, the local medicine concentration is increased, and the bioavailability is improved. The minoxidil liniment disclosed by the invention has excellent skin permeability, can effectively convey a medicine to a required part, and can ensure that the medicine is released at a fixed position of the skin and is accurately administered in a medicine release process, so that the stimulation of liquid medicine flow to other parts is reduced, and a good treatment effect is achieved.

The invention discloses a hair follicle targeting nano-liposome anti-hair loss and hair growth compound preparation. The compound preparation is prepared from the following raw materials in parts by mass: 70 to 85 parts of bionic liposome carrier and 15 to 30 parts of active ingredients, the bionic liposome carrier is prepared from 50 to 60 parts of egg yolk lecithin, 15 to 20 parts of pH sensitive phospholipid DOPE, 10 to 15 parts of cholesterol and 5 to 10 parts of mesenchymal stem cell exosome membrane protein; the active ingredients comprise 5 to 10 parts of minoxidil, 3 to 5 parts of caffeine, 0.5 to 1 part of miR-218-5p, 1 to 2 parts of biotin and 2 to 3 parts of quercetin; the average particle size of the nano-liposome formed by the bionic liposome carrier is 120-180nm, and the polydispersity index (PDI) is less than or equal to 0.15. The invention relates to the technical field of biological medicines, in particular to a hair follicle-targeted nano-liposome anti-hair loss and hair growth compound preparation, which has the following advantages due to the adoption of the technical scheme: accurate targeted delivery is realized, and the treatment safety and accuracy are improved; intelligent response release is achieved, and the local microenvironment of hair follicles is optimized; the multi-target synergistic effect breaks through the limitation of single treatment.

The invention discloses a hair-raising and protecting series composition for treating alopecia as well as a preparation method and application thereof, and relates to the technical field of medicines, and the composition is prepared from minoxidil, propylene glycol, menthol, betaine, an amino acid compound, glycyrrhizic acid, tocopheryl acetate, hinokiol, pyridoxine, ethanol and purified water. The preparation method comprises the following steps: mixing propylene glycol, minoxidil, menthol and ethanol, adding hinokiol, mixing, adding pyridoxine, an amino acid compound and betaine, mixing, adding tocopheryl acetate and glycyrrhizic acid, and mixing. According to the minoxidil composition, the absorption rate of minoxidil can be increased, the drug resistance of the minoxidil composition after being used for a long time is reduced, and the treatment effect of the minoxidil composition on various types of alopecia patients is effectively improved. The invention solves the problem that minoxidil and hinokiol are difficult to dissolve and easy to separate out, has the advantages of good absorption effect and lasting alopecia treatment effect, effectively improves newborn hair quality and scalp greasy state, and brings new dawn to alopecia patients.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The invention relates to the technical field of stem cells, in particular to a serum-free induction medium with definite components for promoting and inducing mesenchymal stem cells to be differentiated into dermal papilla cells and an induction method. The small molecule compound composition is prepared from all-transretinoic acid, calomel, CHIR-99021 and minoxidil according to the molar ratio of (0.2 to 5): (2 to 50): (0.2 to 10): (0.2 to 10). According to the scheme, a plurality of small molecule compounds are adopted and have a synergistic effect, so that differentiation and function improvement of dermal papilla cells are promoted, and transformation of mesenchymal stem cells to the dermal papilla cells is promoted. The former three promote dermal papilla cell differentiation, and the latter promotes dermal papilla cell proliferation and inhibits apoptosis. According to the technical scheme, the technical problems that cell factors need to be added in the process of forming dermal papilla cells from stem cells through induced differentiation, so that the process cost is high, and the clinical safety is not ideal can be solved, the induction process is accelerated, and the method has ideal popularization and application prospects.

The invention belongs to the technical field of pharmaceutical preparations, and discloses a minoxidil solution for androgenetic alopecia, which takes a deep eutectic solvent as a core solvent system and contains 1.0-5.0% of minoxidil (active ingredient), 0.1-1.0% of preservative, 0.05-1% of stabilizer, a proper amount of sodium hydroxide (the pH value is adjusted to 4-9) and purified water. According to the minoxidil solution, the solubility of minoxidil is greatly improved through the deep eutectic solvent, the solubility of minoxidil reaches 779.85 mg / ml and is 389.9 times that of water, the deep eutectic solvent is used in the minoxidil solution, ethanol is not contained, the dosage of propylene glycol is as low as 3%, ethanol and high-dosage propylene glycol (20%-50%) in a traditional commercially available formula are prevented from being used, irritation to scalp is reduced, and the minoxidil solution is suitable for scalp care. The minoxidil solution is stable in content after 6 months under the condition of 40 DEG C / 60% RH, the in-vitro transdermal performance of the minoxidil solution is superior to that of a commercially available reference preparation of an ethanol and propylene glycol solvent system, and the minoxidil solution also has the advantages of high stability, remarkable hair growth ability and the like.

The present invention discloses a PLGA-minoxidil microneedle with near-infrared response and a preparation method thereof. The PLGA-minoxidil microneedle with near-infrared response comprises: PLGA-minoxidil microspheres, lanthanum hexaboride nanoparticles, a matrix, and a needle body; wherein the PLGA-minoxidil microspheres and lanthanum hexaboride nanoparticles are distributed in the needle body; and the materials of the matrix and the needle body are a combination of PVA 1788 and PVA 1799. The present invention combines PLGA-minoxidil microspheres with hydrogel microneedles with near-infrared response. In terms of microstructure, the microporous structure of the microspheres and the near-infrared response of the lanthanum hexaboride nanoparticles cooperate to achieve controlled release of MXD, effectively reduce the side effects of the drug, better maintain the drug concentration in the body, and achieve better therapeutic effects. Macroscopically, the prepared hydrogel system has good mechanical properties and can provide a stable drug delivery channel and drug delivery efficiency.

This disclosure provides a method for treating hair loss in a subject requiring treatment for hair loss, comprising topically administering an effective amount of cortexolone-17α-propionate and an effective amount of minoxidil to the subject. This disclosure further provides a topical pharmaceutical formulation comprising cortexolone-17α-propionate, minoxidil, and one or more pharmaceutically acceptable carriers.

The invention relates to a PDRN-sodium hyaluronate cross-linked double-drug-loading microneedle patch as well as a preparation method and application of the PDRN-sodium hyaluronate cross-linked double-drug-loading microneedle patch. The double-drug-loading microneedle patch is composed of a needle point drug-loading layer and a cross-linked substrate drug-loading layer, the needle point medicine carrying layer is prepared from L-cysteine, L-glutamine, L-arginine, serine, L-lysine hydrochloride, L-proline, glycine, sodium hyaluronate and trehalose; the cross-linked substrate medicine carrying layer is prepared from a PDRN-sulfhydrylated HA copolymer, minoxidil, L-cysteine, L-glutamine, L-arginine, serine, L-lysine hydrochloride, L-proline, glycine and trehalose. The amino acid anti-hair loss and hair growth microneedle system is innovatively developed, a double-drug-loading layered design is adopted, the needle point drug-loading layer is formed by wrapping quick-release amino acid with low-molecular-weight hyaluronic acid (HA), the cross-linked substrate drug-loading layer is formed by wrapping slow-release amino acid, PDRN and minoxidil with high-molecular-weight hyaluronic acid, and instant and long-acting synergy is achieved.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

This invention belongs to the fields of biomedicine and cosmetics, and discloses the application of holly glycoside in promoting hair growth and preventing hair loss. Holly glycoside promotes the transition of hair follicles from the telogen phase to the anagen phase (i.e., shortening the telogen phase and prolonging the anagen phase), and inhibits cyclophosphamide-induced apoptosis of hair follicle cells and DHT-induced miniaturization of hair follicles. In androgenetic alopecia, telogen effluvium, and chemical alopecia models, its hair growth-promoting effect is comparable to that of the positive control drug minoxidil. It has broad application prospects in pharmaceutical formulations, cosmetics, skincare products, and beauty products.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The invention discloses an androgen alopecia slow-release therapeutic agent. The androgen alopecia slow-release therapeutic agent is rhizoma drynariae extracellular vesicles; or the rhizoma drynariae extracellular vesicles are compounded with minoxidil. The androgen alopecia slow-release therapeutic agent can effectively inhibit human hair follicle cell apoptosis and oxidative stress induced by dihydrotestosterone, and has excellent hair follicle targeting property and safety; the invention belongs to the technical field of medicine.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The invention discloses a hair-growing liniment and a preparation method thereof, and belongs to the technical field of pharmacy. The liniment comprises the following components in percentage by weight: 1-10% of minoxidil microspheres, 5-20% of a film-forming agent, 0.5-5% of a polypeptide compound, 5-30% of a liquid auxiliary material and the balance of deionized water. Wherein the minoxidil microspheres are of a three-layer structure composed of minoxidil in the inner layer, nano enzyme (cerium dioxide) in the middle layer and lactic acid-glycolic acid ester copolymer or chitosan in the outer layer, and controlled release and targeted delivery are achieved; the polypeptide compound is a compound of oldenlandia diffusa polypeptide and a copper curcumin derivative, and has the effect of synergistically repairing a hair follicle microenvironment. Tests prove that the liniment can remarkably prolong the release time of minoxidil, increase the retention volume of minoxidil in hair follicle parts and reduce absorption of the whole body, shows a hair growth promoting effect superior to that of a traditional preparation and a single-layer microsphere preparation in an animal model, and has good stability and use comfort.

This disclosure relates to a single pharmaceutical composition comprising a therapeutically effective or prophylactically effective amount of both minoxidil, or a similar antihypertensive vasodilator, and a 5-alpha reductase inhibitor (in some embodiments, the 5-alpha reductase inhibitor is finasteride) for treating or preventing hair loss in a subject. This disclosure also relates to a pharmaceutical package comprising a pharmaceutical composition for oral administration of a therapeutically effective or prophylactically effective amount of minoxidil, or a similar antihypertensive vasodilator, and a pharmaceutical composition for oral administration comprising a therapeutically effective or prophylactically effective amount of a 5-alpha reductase inhibitor (in some embodiments, the 5-alpha reductase inhibitor is finasteride) for treating or preventing hair loss in a subject. The disclosure further provides methods of treating or preventing hair loss in a subject using the disclosed compositions and packages.

The present invention refers to an oral pharmaceutical composition comprising minoxidil having controlled particle size for the treatment of androgenetic alopecia, as well as a medicament, methods for treatment and associated uses.

The invention relates to a hair-growing traditional Chinese medicine composition for strengthening hair roots and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine hair-growing preparations. The composition comprises a composite traditional Chinese medicine fermentation extract prepared by fermenting black sesame, walnut kernels, almonds and polygonum multiflorum according to a specific proportion through CFU / mL lactobacillus plantarum, and is compounded with a prepared rehmannia root extract, an angelica sinensis extract, a cacumen biotae extract, a ginkgo leaf extract and the like according to a specified proportion. The preparation method comprises the steps of raw material treatment, fermentation, enzymolysis extraction, compound blending and the like. The composition is free of chemical solvents and minoxidil, free of irritation, fast in absorption, excellent in stability and remarkable in strengthening and hair growing effect, and can be used for preparing hair growing liquid, hair growing cream, hair nourishing essence and the like.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The present disclosure provides a method of treating hair loss in a subject in need thereof, comprising administering to the surface of the subject an effective amount of picosterone-17a-propionate and an effective amount of minoxidil. The present disclosure also provides surface pharmaceutical formulations comprising picosterone-17a-propionate, minoxidil, and one or more pharmaceutically acceptable carriers.

The present disclosure provides a method of treating hair loss in a subject in need thereof, comprising topically administering to the subject an effective amount of cortexolone-17α-propionate and an effective amount of minoxidil. The present disclosure further provides a topical pharmaceutical formulation comprising cortexolone-17α-propionate, minoxidil, and one or more pharmaceutically acceptable carriers.

The present application relates to a kind of minoxidil external solution and its preparation process, including 3 portions minoxidil, 30-40 portions ethanol, 5-7 portions propylene glycol, 0.005-0.02 portions antioxidant, 0.1-0.3 portions chelating agent, 58-60 portions purified water.The present application adds suitable antioxidant and chelating agent, so that minoxidil external solution reduces the generation of oxidation reaction in storage and use process, effectively prevents the problem of long-term storage discoloration, and the stability of the minoxidil external solution is high.By improving the formula and filtering process, microporous filter membrane is used for the original liquid, and repeated filtration is at least 2 times, and the filtration pressure and filtration temperature are repeatedly changed every minute;Finally, the amount of minoxidil adsorbed and retained by microporous filter membrane during filtration is very low (adsorption rate is less than 0.5%), which is significantly lower than the existing level, the stability of the effective component of product is high, and the qualified rate of product is significantly improved.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

A pharmaceutical composition containing minoxidil, which is composed of minoxidil, a filler, a sustained-release material, a glidant and a lubricant, wherein the specification of minoxidil is 1.25-5.0 mg, and the sustained-release material is selected from hypromellose. The minoxidil composition has a sustained-release effect of 8-12 hours in vitro, has an ideal in-vivo plasma concentration and bioavailability, and ensures the safety and effectiveness of the use of minoxidil.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.